Trial Profile

A Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SOF SKN (Primary)
Indications Cutaneous lupus erythematosus
Focus Adverse reactions; First in man; Proof of concept
Acronyms HERACLES
Sponsors Noxopharm

Most Recent Events

21 Jan 2026 According to a Noxopharm media release, the second and final multiple-dose cohort of SOF-SKN has been finished in the trial.
21 Jan 2026 Status changed from recruiting to completed.
17 Nov 2025 According to a Noxopharm media release, the company will secure federal R&D tax benefits by conducting the study locally in Australia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com